To assess whether IRS4-mediated resistance would occur spontaneously in HER2+ breast cancer cell lines, we cultured naive cell lines for five passages in medium containing increasing concentrations of Trastuzumab or Lapatinib. The gene discussed is ERBB2; the disease is breast carcinoma.